Jason is an investor with the Private Investments team focusing on mid- to late-stage private biotech companies developing clinically impactful new medicines. He is responsible for sourcing investment opportunities, leading due diligence, evaluating and negotiating deal terms, and managing the investments until their exit.

Jason leverages his investor network and scientific background to identify and diligence private investment opportunities. He partners across the private and public investment teams to build a detailed, integrated understanding of how individual investments align with scientific innovation, clinical developments, and broader market dynamics.

Prior to joining Wellington Management in 2024, Jason was a Partner with MRL Ventures, the corporate venture capital arm of Merck (2022 – 2024). Jason began his investing career at 5AM Ventures (2017 – 2022) where he started in early-stage biotech venture capital and venture creation, and from 2020 – 2022 helped establish the firm’s public investment activities. Before this, he conducted cancer research at the Broad Institute with Levi Garraway from 2014 - 2016.

Jason earned his PhD in biomedical engineering from the University of Pennsylvania in 2014 as a Howard Hughs Medical Institute fellow, and his BS in bioengineering from the University of California in Irvine as a UCLEADS scholar in 2007.

Jason volunteers as a member of the Scientific Advisory Board for the nonprofit Every Cure and previously volunteered as the Chief Scientific Officer and a member of the Scientific Advisory Board for the nonprofit Castleman Disease Collaborative Network.